Italia markets open in 6 hours 14 minutes

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
4,1900+0,0300 (+0,72%)
Alla chiusura: 04:00PM EDT
4,2200 +0,03 (+0,72%)
Dopo ore: 05:24PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,1600
Aperto4,1500
Denaro4,1300 x 300
Lettera4,2100 x 800
Min-Max giorno4,1500 - 4,2900
Intervallo di 52 settimane3,1700 - 5,7500
Volume1.761.688
Media Volume2.872.996
Capitalizzazione1,134B
Beta (5 anni mensile)1,32
Rapporto PE (ttm)N/D
EPS (ttm)-0,0400
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,08
  • GlobeNewswire

    MannKind Corporation Announces Participation at Upcoming Conferences

    WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. H.C. Wainwright 25th Annual Global Investment Conference – Monday, September 11, 2023 at 8:30 am (ET) Morgan Stanley 21st Annual Global Healthcare Conferen

  • GlobeNewswire

    MannKind Corporation Reports 2023 Second Quarter Financial Results

    Conference Call to Begin Today at 5:00 p.m. (ET) 2Q 2023 Total revenues of $49M; +157% vs. 2Q 2022 2Q 2023 Tyvaso DPI royalties of $19M; +63% vs. 1Q 20232Q 2023 Endocrine Business Unit net revenues of $18M; Afrezza net revenues +27% vs. 2Q 20222Q 2023 Income from operations of $2M; Non-GAAP income from operations of $8M DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended June 30,

  • GlobeNewswire

    MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 at the Lotte Palace in New York Ci